What is a direct-to-patient model: guide for UK pharma

A direct-to-patient (DTP) model is a clinical delivery model that joins telehealth assessment, prescribing, regulated dispensing and logistics to get medicines into patients' hands outside traditional clinic or hospital settings. The core components are a digital front door for triage, a prescribing layer (private or delegated), a GPhC-registered pharmacy for dispensing, temperature-controlled fulfilment, and a data layer that ties the whole pathway together. The prime benefit is a shorter time to therapy and improved access for patients who would otherwise face long waits or geographic barriers.

There is a critical UK regulatory boundary you need to understand from the outset. Manufacturers cannot ship prescription-only medicines directly to patients. Every compliant DTP programme in the UK must partner with GPhC-registered pharmacies for dispensing and CQC-regulated prescribers or private-prescribing pathways for the clinical decision. That legal split shapes every contract, every governance structure, and every technology integration in a UK DTP programme.

Why is DTP gaining momentum right now?

The forces driving DTP adoption are structural, not cyclical. BCG's analysis identifies regulatory initiatives, rising consumer expectations and AI-enabled digital platforms as the primary accelerants, and notes there is no single DTP model — only guiding principles for patient-centred design.

Several drivers are converging at once:

• Consumer expectations have shifted. Patients who order prescriptions online and track deliveries in real time expect the same from specialist medicines. The pandemic normalised remote consultations and home delivery across the NHS and private sector alike.
• Digital health platforms have matured. Asynchronous triage, electronic prescribing, and integrated pharmacy management systems now exist at a price point that makes DTP commercially viable for mid-sized programmes, not just large pharma.
• Therapy demand is outpacing traditional supply routes. GLP-1 treatments such as Wegovy and Mounjaro have created a demand surge that GP and hospital outpatient systems cannot absorb at pace. DTP pathways are filling that gap.
• Supply chain innovation has reduced cold-chain risk. Validated temperature-controlled packaging, real-time monitoring and proof-of-delivery technology have made home delivery of biologics and injectables operationally credible.
• Regulatory frameworks are catching up. The Health Research Authority's position on decentralised trial methods has opened a clearer pathway for DTP in clinical research, reducing the ambiguity that previously deterred sponsors.

The expected benefits map neatly onto these drivers. Speed to therapy improves when patients bypass referral queues. Adherence tends to increase when medicines arrive at home with structured follow-up built in. Personalised care becomes achievable when a data layer captures patient behaviour and flags non-adherence early. For manufacturers, DTP can reduce patient acquisition cost where demand is already high. For health systems, reduced emergency presentations linked to poor adherence represent a meaningful, if harder-to-quantify, saving.

Statistic callout: Remote pharmaceutical care and home delivery increase access and adherence for many patients — but may reduce time available for comprehensive pharmaceutical care, particularly for those requiring complex counselling. That trade-off must be designed out, not ignored.

Where does DTP deliver the most value?

Not every therapy is a natural fit. The programmes that generate sustainable return on investment tend to share a few characteristics: high patient demand, a condition where adherence directly affects outcomes, and a supply chain that can be validated for home delivery.

Clinical trials and IMP delivery

Decentralised and hybrid clinical trials are one of the fastest-growing DTP use cases in the UK. Direct-to-patient delivery of investigational medicinal products must be explicitly documented in the approved protocol, with robust risk assessment, patient consent and validated temperature-controlled logistics. When those controls are in place, DTP reduces participant burden, improves recruitment in rare disease populations, and supports retention across geographically dispersed cohorts. The Health Research Authority's decentralised trial toolkit from the Association of Clinical Research Organisations provides practical resources for sponsors designing these pathways.

Speciality medicines and rare disease hubs

Hub-and-spoke models for speciality medicines are a well-established DTP variant. A central clinical hub manages complex initiation, monitoring and adverse event reporting; home delivery handles ongoing supply. The patient avoids repeated hospital visits for stable therapy. This model suits biologics, immunosuppressants and orphan medicines where the clinical complexity sits at initiation rather than maintenance.

Chronic therapies where adherence matters

Conditions such as hypertension, type 2 diabetes, and hypothyroidism are strong candidates. The clinical assessment is straightforward, monitoring can be done remotely or via periodic blood tests, and the consequence of a missed dose is measurable. Structured follow-up built into the DTP pathway — automated reminders, pharmacist check-ins, dose titration support — can meaningfully improve adherence rates compared with a standard repeat-prescription model.

Digital-first services for high-demand indications

Weight management is the clearest current example. Demand for GLP-1 weight loss treatments has outpaced NHS capacity, and private DTP services have stepped in to provide clinician-led assessment, private prescribing and home delivery at scale. The same pattern is visible in erectile dysfunction, hair loss and certain dermatology indications.

Where DTP is a poor fit: conditions requiring complex initiation with face-to-face monitoring, therapies with narrow therapeutic indices where remote monitoring is insufficient, controlled drugs with strict dispensing requirements, and any indication where the patient population has low digital literacy or unreliable internet access.

Pro Tip: Pharmaphorum's five-question framework is a useful starting screen: define what DTP means for your programme, clarify who owns the patient relationship, assess product fit, map your infrastructure, and agree how you will measure success before committing to a build.

How does a DTP programme actually work end to end?

Think of a DTP programme as three layers sitting on top of a shared data spine: a clinical layer, a fulfilment layer, and an analytics layer. Successful providers orchestrate the full patient journey using data and modular service blocks rather than building a monolithic system.

The patient journey, step by step

1. Patient identification and outreach. Patients are identified through referral, self-referral, or digital marketing. A digital front door (web or app) captures initial information and screens for eligibility.
2. Digital triage and telehealth assessment. An asynchronous questionnaire or synchronous video consultation with a registered clinician determines clinical suitability. This is where safeguarding checks, contraindication screening and informed consent happen.
3. Prescribing. A CQC-regulated prescriber issues a private prescription or, in trial settings, follows the protocol-defined prescribing pathway. Clinical accountability must sit with a named, accountable clinical lead — not distributed across a platform.
4. Dispensing via a GPhC-registered pharmacy. The prescription is transmitted electronically to the dispensing pharmacy. The pharmacist performs a clinical check, labels the medicine and prepares it for dispatch.
5. Secure fulfilment and returns. Temperature-controlled packaging, tracked courier services, proof-of-delivery confirmation and a returns pathway for unused or damaged stock. Cold-chain integrity must be validated, not assumed.
6. Follow-up and adherence support. Automated check-ins, pharmacist-led medication reviews, dose titration support and adverse event reporting pathways. This is where DTP earns its clinical credibility — or loses it.

Operational building blocks

• Clinical governance framework: standard operating procedures, prescribing delegation protocols, adverse event reporting, and a named clinical lead with clear accountability.
• Digital platform: electronic prescribing, patient records, consent management, and integration with the dispensing pharmacy's system.
• Hub services: for complex speciality medicines, a clinical hub manages initiation, monitoring and escalation.
• Logistics: validated cold-chain packaging, courier SLAs, proof-of-delivery capture, and a returns and waste management process.
• Payments and reimbursement: patient payment processing, insurer or commissioner invoicing where applicable, and reconciliation with the dispensing pharmacy.
• Data integration and reporting: a central data layer connecting clinical, dispensing and logistics data to generate real-time KPIs and support pharmacovigilance.

Pro Tip: The prescribing-to-dispensing handoff is the most common point of clinical risk in a DTP programme. Define in your governance documentation exactly who holds clinical accountability at each handoff — and make sure that person is reachable when something goes wrong.

What are the UK regulatory requirements for a DTP programme?

The legal boundary is non-negotiable. Manufacturers are prohibited from dispatching prescription-only medicines directly to patients in the UK. The compliant route is a partnership model: a manufacturer or programme sponsor orchestrates the pathway, while a GPhC-registered pharmacy dispenses and a CQC-regulated prescriber issues the prescription. Understanding the UK prescription process is foundational before designing any DTP pathway.

Compliance checklist

• MHRA: Medicines must be licensed for the indication, or used under a named-patient or specials licence where applicable. Pharmacovigilance obligations apply to the marketing authorisation holder. For clinical trials, the MHRA must authorise the Clinical Trial Authorisation (CTA) and any protocol amendments that introduce DTP delivery.
• GPhC: All dispensing must be carried out by a GPhC-registered pharmacy. Distance-selling pharmacies must operate with national coverage and are prohibited from dispensing to walk-in patients at the same premises. Pharmacy accreditation, standard operating procedures and responsible pharmacist requirements all apply.
• CQC: Where the DTP programme constitutes a regulated activity (providing treatment or diagnostic services), the provider must be CQC-registered. This typically applies to the prescribing service, not the dispensing pharmacy.
• ICO: Patient data collected, processed and shared across the DTP pathway must comply with UK GDPR and the Data Protection Act 2018. Data processing agreements must be in place with all third-party processors, including logistics providers who capture proof-of-delivery data.
• IMP-specific requirements: For clinical trials, DTP delivery of investigational medicinal products must be included in the approved protocol, with validated temperature-controlled logistics, proof-of-delivery documentation and explicit patient consent for home delivery.

Operational controls

Beyond registration and licensing, a compliant DTP programme needs:

• Written prescribing delegation protocols and supervision arrangements.
• Cold-chain certification for any medicine requiring temperature control (typically 2–8°C for biologics).
• Proof-of-delivery records retained for audit purposes.
• A documented adverse event reporting pathway that meets MHRA Yellow Card requirements.
• Regular clinical governance reviews with documented minutes and action logs.
• Pharmacy accreditation checks at partner selection and at defined intervals thereafter.

Regulatory note: The MHRA, GPhC, CQC and ICO each publish guidance relevant to DTP programmes. Treat their published standards as the floor, not the ceiling, of your compliance framework.

What are the main risks and how do you mitigate them?

DTP is not a risk-free shortcut to market. The programmes that fail tend to underestimate clinical risk, overestimate logistics reliability, or ignore the equity implications of a digital-first model.

Clinical risks

• Inappropriate prescribing is the most serious risk. Without face-to-face assessment, contraindications can be missed. Mitigation: structured clinical decision support tools, mandatory contraindication screening, and a clinical governance framework with regular audit.
• Reduced therapeutic oversight for complex conditions. Mitigation: define monitoring requirements before launch and build them into the follow-up pathway, not as an afterthought.
• Difficulty managing complex initiations. Some therapies require titration, monitoring blood tests or specialist review at initiation. DTP is not appropriate for these without a hybrid model that includes face-to-face touchpoints.

Operational risks

• Logistics failures and cold-chain breaches. A single temperature excursion can render a biologic ineffective and create a patient safety incident. Mitigation: validated packaging, real-time temperature monitoring and a clear protocol for what happens when a breach is detected.
• Proof-of-delivery failures. If a medicine is not received, the patient may go without treatment or seek an unsafe alternative. Mitigation: tracked delivery with patient confirmation, and a same-day escalation pathway.
• Stock integrity. Returns, wastage and diversion must be managed with documented processes.

Equity and access risks

Remote pharmaceutical care can widen inequalities if the digital front door excludes patients with low digital literacy, unreliable internet access, or disabilities that make online assessment difficult. Geographic coverage gaps in courier networks can leave rural patients underserved. Monitoring equity metrics from day one is not optional — it is a governance responsibility.

Commercial and regulatory risks

• Reimbursement uncertainty: NHS commissioning of DTP services is inconsistent, and private-pay models depend on sustained patient demand.
• Contractual exposure: unclear liability allocation between sponsor, prescriber and pharmacy creates risk when things go wrong.
• Reputational harm: a single high-profile patient safety incident in a DTP programme attracts disproportionate regulatory and media scrutiny.

Red flags to include in partner contracts: defined SLAs for cold-chain integrity, explicit liability allocation for dispensing errors, mandatory adverse event reporting timelines, and a right to audit pharmacy operations.

How do you decide whether DTP is right for your programme?

The decision is not binary. Most programmes benefit from a structured go/no-go assessment before committing to a full build. Industry commentary consistently warns against adopting DTP solely for optics; programmes that address a specific access friction and have measurable return on investment tend to be the ones that survive beyond the pilot phase.

Go/no-go checklist

1. Patient demand and awareness: Is there demonstrated unmet demand? Do patients know the therapy exists and want it?
2. Condition suitability: Can clinical assessment be conducted safely and thoroughly via telehealth? Is ongoing monitoring achievable remotely?
3. Monitoring complexity: Does the therapy require frequent blood tests, imaging or specialist review? If yes, a hybrid model is likely needed.
4. Supply chain feasibility: Can the medicine be delivered safely to a home address? Is cold-chain validation achievable at the required scale?
5. Regulatory pathway: Is the prescribing pathway clearly defined? Are GPhC-registered dispensing partners identified?
6. Commercial value case: Does the programme generate sufficient margin to sustain clinical governance investment?
7. Stakeholder readiness: Are prescribers, pharmacists and logistics partners aligned on roles and accountability?

How does Lyvpharmacy demonstrate DTP in practice?

Lyvpharmacy operates as a clinician-led online pharmacy in the UK, and its model illustrates what a compliant, patient-centric DTP pathway looks like in practice for high-demand indications.

The pathway runs as follows: a patient completes a structured online clinical assessment, reviewed by a registered clinician who determines eligibility based on defined clinical criteria. Where appropriate, a private prescription is issued. Dispensing is carried out by a GPhC-registered pharmacy, and medicines are dispatched for next-day delivery in appropriate packaging. Follow-up is built into the pathway, not appended.

The governance features that make this model compliant and credible include:

• Registered clinicians conducting every assessment, with clear accountability for the prescribing decision.
• Transparent clinical criteria published for patients, so eligibility is not opaque.
• Audit trails maintained across assessment, prescribing and dispensing for regulatory review.
• Patient follow-up processes that support adherence and flag safety concerns early.
• GPhC-registered dispensing at every stage, meeting the legal requirement for prescription medicine supply.

For healthcare and pharma professionals evaluating DTP design, Lyvpharmacy's approach to clinician-guided care demonstrates that speed and clinical rigour are not mutually exclusive. The model also shows how online healthcare safety can be maintained when governance is treated as a design requirement rather than a compliance afterthought.

Note: Lyvpharmacy operates as a private prescribing service. Clinical eligibility criteria apply to all patients.

Operational checklist for launching a DTP programme

Pre-launch

1. Establish clinical governance. Appoint a named clinical lead. Draft standard operating procedures for prescribing, dispensing, adverse event reporting and escalation. Define the monitoring framework for the therapy.
2. Secure regulatory sign-off. Confirm CQC registration for the prescribing service, GPhC registration for the dispensing pharmacy, MHRA compliance for the medicine, and ICO registration for data processing.
3. Select and contract partners. Evaluate dispensing pharmacies against GPhC accreditation, cold-chain capability, SLA performance and audit rights. Do the same for logistics providers.
4. Build and test the digital platform. Electronic prescribing, patient records, consent management and pharmacy integration must be tested end-to-end before go-live.
5. Conduct cold-chain validation. Test packaging performance across the temperature range the medicine requires, including worst-case scenarios for transit time and ambient temperature.

Launch

6. Design the pilot cohort. Define patient eligibility, recruitment pathway and consent process. Set KPI baselines.
7. Train clinical and pharmacy teams. Cover the clinical protocol, the digital platform, the escalation pathway and the adverse event reporting process.
8. Monitor SLAs in real time. Track delivery success rates, cold-chain integrity, time to therapy and patient satisfaction from day one.
9. Activate contingency plans. Define what happens when a delivery fails, a cold-chain breach occurs, or a patient reports an adverse event.

Scale

10. Review pilot KPIs against pre-set thresholds. Use the go/no-go matrix to make a structured scale decision.
11. Plan capacity. Model demand scenarios and ensure dispensing and logistics partners can scale without compromising SLAs.
12. Implement continuous improvement loops. Monthly clinical governance reviews, quarterly pharmacy audits, and regular patient feedback analysis.
13. Develop reimbursement strategy. For NHS-adjacent programmes, engage commissioners early. For private-pay models, monitor unit economics and patient retention.
14. Maintain post-launch safety surveillance. Pharmacovigilance obligations do not end at launch. Adverse event data must feed back to the marketing authorisation holder and, where required, to the MHRA.

Sustainable DTP models invest in clinical governance, data-driven monitoring and ongoing patient services — not just dispatch volume. That investment is what separates programmes that scale from those that stall after the pilot.

Key takeaways

A direct-to-patient model is only as strong as its clinical governance: UK law requires GPhC-registered dispensing and CQC-regulated prescribing, and programmes that treat these as design requirements rather than compliance boxes tend to deliver better patient outcomes and longer commercial viability.

Point - Details

Legal boundary is fixed

UK manufacturers cannot ship prescription-only medicines directly to patients; GPhC and CQC partnerships are mandatory.

Fit before build

Assess condition suitability, monitoring complexity and supply chain feasibility before committing to a DTP programme.

Governance is the differentiator

Programmes that invest in clinical governance, audit trails and follow-up outperform those optimised for dispatch volume alone.

Equity must be monitored

Digital exclusion and geographic coverage gaps can widen inequalities; track equity metrics from day one.

Lyvpharmacy as a working model

Lyvpharmacy demonstrates compliant DTP delivery with registered clinicians, GPhC dispensing, and next-day UK delivery for high-demand indications.

What practitioners often get wrong about DTP

The most common mistake is treating DTP as a logistics problem. It is not. It is a clinical delivery problem that happens to involve logistics. Programmes designed around dispatch efficiency — fast, cheap, high volume — tend to run into clinical governance failures within 12–18 months. A prescribing error that goes undetected because there is no follow-up pathway, or a cold-chain breach that is not escalated because no one owns the protocol, can end a programme faster than any commercial headwind.

The second blind spot is the equity question. Digital-first models naturally attract digitally confident patients. That is fine commercially, but it creates a systematic gap for patients with lower digital literacy, disabilities, or unreliable connectivity. If your programme is commissioned or publicly funded, that gap is a regulatory liability. Even in private-pay models, ignoring it narrows your addressable market and creates reputational risk.

Three practical actions for teams starting a DTP programme:

1. Clinical governance first. Before you write a line of platform code or sign a logistics contract, appoint a named clinical lead and draft your standard operating procedures. Everything else depends on that foundation.
2. Prioritise continuity of care. Design the follow-up pathway at the same time as the onboarding pathway. A patient who receives their first prescription and then hears nothing is a patient at risk.
3. Monitor equity metrics from day one. Track who is not completing the digital triage, not receiving deliveries on time, or dropping out of the programme. That data tells you where the model is failing the patients who need it most.

The regulatory duty of care does not end when the medicine leaves the pharmacy. In a DTP model, the clinical lead, the prescriber and the dispensing pharmacist all carry ongoing responsibilities. Designing those responsibilities into the governance structure from the start is what separates a programme that earns trust from one that merely processes orders.

Lyvpharmacy: a clinician-led DTP pathway built for the UK

If you are evaluating what a compliant, patient-centric DTP service looks like in practice, Lyvpharmacy offers a clear reference point. Every patient goes through a structured clinical assessment with a registered clinician before any prescription is issued. Dispensing is carried out by a GPhC-registered pharmacy, and medicines are delivered to patients' doors with next-day UK delivery as standard.

The model covers high-demand prescription treatments including GLP-1 weight loss medicines such as Wegovy and Mounjaro, alongside hair loss, erectile dysfunction and skincare treatments. Clinical eligibility criteria apply to every patient, and the pathway is designed around continuity of care rather than one-off dispensing. There are no mandatory subscriptions — patients pay per treatment, with the clinical assessment included in the treatment price.

For healthcare and pharma professionals looking to understand how a regulated DTP pathway operates in the UK, Lyvpharmacy's model demonstrates that fast access and clinical rigour can coexist. This service operates as a private prescribing pathway. Clinical eligibility criteria apply. Always confirm suitability with a registered clinician.

Explore Lyvpharmacy's treatments to see how a compliant, clinician-led DTP pathway is structured for UK patients.

Recommended

• LYV Pharmacy GPhC Registration UK
• Pricing | LYV